Back to top
more

Henry Schein (HSIC)

(Delayed Data from NSDQ)

$67.37 USD

67.37
1,569,064

-1.02 (-1.49%)

Updated Sep 17, 2025 04:00 PM ET

After-Market: $67.49 +0.12 (0.18%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 245)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why You Should Retain Catalent (CTLT) Stock for Now

by Zacks Equity Research

Catalent's (CTLT) product and service launches, and a slew of strategic deals raise optimism about the stock.

Zacks Equity Research

Here's Why Investors Should Buy Bio-Rad (BIO) Stock Now

by Zacks Equity Research

Investors are optimistic about Bio-Rad (BIO) on robust growth in Life Science and Clinical Diagnostics arms.

Zacks Equity Research

Thermo Fisher (TMO) Expands to Boost Commercial Manufacturing

by Zacks Equity Research

Thermo Fisher's expansion in Bourgoin is built on the company's investments in small molecule solutions.

Zacks Equity Research

Encompass Health (EHC) Up 32% in 6 Months: More Room to Run?

by Zacks Equity Research

Encompass Health (EHC) is well-poised for growth on the back of growing facility count within its Inpatient Rehabilitation segment and sound liquidity position.

Zacks Equity Research

3 Reasons to Retain Ecolab (ECL) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Ecolab (ECL) owing to its strong business.

Zacks Equity Research

PacBio's (PACB) New Offering to Enable High-Throughput Workflows

by Zacks Equity Research

PacBio's (PACB) latest launch is expected to combine the power of HiFi sequencing and Nanobind technology to optimize sample preparation workflows for its high-volume customers.

Zacks Equity Research

Best Growth Stocks to Buy for April 11th

by Zacks Equity Research

CROX, HSIC and PANW made it to the Zacks Rank #1 (Strong Buy) growth stocks list on April 11, 2023.

Zacks Equity Research

Henry Schein (HSIC) Acquires Majority Stake in Biotech Dental

by Zacks Equity Research

Henry Schein (HSIC) announces that the completion of the Biotech Dental partnership brings forth the company's several important solutions to customers.

Zacks Equity Research

Henry Schein (HSIC) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Henry Schein (HSIC) closed at $83.89, marking a -0.99% move from the previous day.

Zacks Equity Research

Baxter's (BAX) New Premix Drug Now Available in the U.S.

by Zacks Equity Research

Baxter's (BAX) latest frozen premix formulation is expected to support patient safety, simplify medication preparation and boost operational efficiencies.

Zacks Equity Research

Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now

by Zacks Equity Research

Investors are optimistic about IDEXX's (IDXX) strength in the Companion Animal Group business.

Zacks Equity Research

CVS Health (CVS) Team Up to Treat Digestive Disorder Virtually

by Zacks Equity Research

CVS Health's (CVS) recent partnership with Oshi makes it possible for its members to receive coordinated virtual digestive treatment.

Zacks Equity Research

Here's Why You Should Retain Intuitive Surgical (ISRG) Stock Now

by Zacks Equity Research

Investors continue to be optimistic about Intuitive Surgical (ISRG) owing to its strength in robotics.

Zacks Equity Research

QIAGEN's (QGEN) Expanded Test Menu Aids, FX Woe Lingers

by Zacks Equity Research

In terms of QIAstat-Dx, QIAGEN (QGEN) continues to witness increased demand for system placements and growing consumables usage around the world.

Zacks Equity Research

National Vision (EYE) Rides on Comps Growth Amid Macro Issues

by Zacks Equity Research

National Vision (EYE) continues to roll out its remote care capabilities, which provide doctors with additional levels of flexibility and expand exam capacity in many areas.

Zacks Equity Research

Here's Why You Should Add Stryker (SYK) Stock to Your Portfolio

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on the company.

Zacks Equity Research

Here's Why You Should Retain Surmodics (SRDX) Stock for Now

by Zacks Equity Research

Investors continue to feel optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.

Zacks Equity Research

Illumina (ILMN) to Expand Genomics Capacity With New Pact

by Zacks Equity Research

Illumina's (ILMN) recent collaboration is built on the shared goal of the organizations to expand sequencing capabilities and capacity for all people in Africa.

Zacks Equity Research

Here's Why Investors Should Invest in Zimmer Biomet (ZBH) Now

by Zacks Equity Research

Investors are optimistic about Zimmer Biomet (ZBH) on strong elective procedure recovery and commercial execution.

Zacks Equity Research

Best Growth Stocks to Buy for April 6th

by Zacks Equity Research

ASUR, RL and HSIC made it to the Zacks Rank #1 (Strong Buy) growth stocks list on April 6, 2023.

Zacks Equity Research

Illumina's (ILMN) NovaSeq X Exceeds 200 Order Milestone

by Zacks Equity Research

Illumina's (ILMN) NovaSeq X records the strongest pre-launch demand ever witnessed for any instrument.

Zacks Equity Research

3 Reasons to Retain Integer Holdings (ITGR) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Integer Holdings (ITGR) owing to its improving non-medical sales and a solid foothold in the broader MedTech space.

Zacks Equity Research

Here's Why You Should Retain Inari Medical (NARI) Stock Now

by Zacks Equity Research

Inari Medical (NARI) continues to benefit from its commitment to understand the venous system. However, its dependency on the adoption of products is concerning.

Zacks Equity Research

CVS Health's (CVS) New Initiatives Aid, Margin Woes Linger

by Zacks Equity Research

CVS Health (CVS) launches functionality that gives patients more choices and convenience in filling prescriptions.

Vasundhara Sawalka headshot

4 Stocks Trading Near 52-Week High That Can Climb Further

by Vasundhara Sawalka

Investors target stocks that have been on a bullish run lately. Stocks like MYRG, HSIC, KR and COTY, which are seeing price strength, have a high chance of carrying the momentum forward.